Drug Profile
YY 201
Alternative Names: YY201Latest Information Update: 11 Apr 2024
Price :
$50
*
At a glance
- Originator Yuyu
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Haematological malignancies; Non-small cell lung cancer; Solid tumours
- No development reported Benign prostatic hyperplasia
Most Recent Events
- 11 Apr 2024 Phase-I clinical trials in Non-small cell lung cancer (PO) (Shanghai Yuyao Biotech pipeline, April 2024)
- 26 Oct 2023 Phase-I clinical trials in Haematological malignancies in China (PO) (NCT06225856)
- 26 Oct 2023 Phase-I clinical trials in Solid tumours in China (PO) (NCT06225856)